Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2007

01-12-2007 | Research Article

Drug therapy problems found in ambulatory patient populations in Minnesota and South Australia

Authors: Deepa Rao, Andrew Gilbert, Linda M. Strand, Robert J. Cipolle

Published in: International Journal of Clinical Pharmacy | Issue 6/2007

Login to get access

Abstract

Objective

To compare drug therapy problems identified by pharmacists in two patient samples, the Minnesota Sample and the South Australian Sample.

Methods

Two patient samples were selected for this comparison. Both sets of patients received pharmaceutical care services from pharmaceutical care practitioners between March 1999 and February 2000. The two databases were then compared for common drug therapy problems.

Main outcome measure

Comparison of drug therapy problems in the two samples.

Results

Both patient samples included patients who were 40 years of age or older. The Minnesota Sample included 1,598 individual patients, of whom 70% experienced one or more drug therapy problems at some time during their care. The South Australian Sample included a total of 982 patients of whom 90% experienced one or more drug therapy problems at some time during their care. Conditions common to both patient samples include hypertension, diabetes, arthritis, ischemic heart disease, and osteoporosis. Frequently occurring drug therapy problems in the Minnesota Sample included the need for additional drug therapy, dosage too low and non-compliance and in the South Australian Sample included non-compliance, additional drug therapy and ineffective drug therapy. Frequent drug therapy problems associated with medical conditions in the Minnesota Sample included addition of new therapies for conditions such as arthritis, hypertension, hyperlipidemia and allergic rhinitis, while for the South Australian Sample included compliance issues with conditions such as asthma, diabetes mellitus, angina and digestive disorders. Frequent drug therapy problems with associated drug classes in the Minnesota Sample included additional therapy for classes such as salicylates and calcium supplements, while in the South Australian Sample included the need for therapy for pneumococcal vaccines, salicylates, calcium supplements and tetanus vaccines.

Conclusion

These data demonstrate that this age group has significant drug therapy problems and therefore emphasize the need for pharmaceutical care services in this population. The provision of pharmaceutical care by experienced practitioners can result in improved recognition of the full range of drug therapy problems confronting patients. Analyses such as those presented here provide information to better focus the training of practitioners based on the most frequently encountered health problems and the nature of common drug therapy problems in the community setting.
Footnotes
1
The Assurance Pharmaceutical Care system is an electronic charting system specifically designed to help provide, document, and evaluate pharmaceutical care practice. This Windows-based clinical system creates an Electronic Therapeutic Record© through the collection of patient demographic data, patient-specific care planning, medication documentation, drug interaction checking, drug therapy problem identification, follow-up evaluations, physician and patient reporting, and clinical and economic outcome tracking. The practice management portion of the system supports data consolidation among numerous practitioners including workload tracking, billing, quality improvement evaluation reports, population efficacy, safety and economic evaluations by product, disease, practitioner or group practice. To date, over 75,000 patient encounters have been documented using this system.
 
Literature
1.
go back to reference March G, Gilbert AL, Roughead EE, Quintrell N. Developing, evaluating a model for pharmaceutical care in Australian community pharmacies. Int J Pharm Pract 1999;7(4):220–9. March G, Gilbert AL, Roughead EE, Quintrell N. Developing, evaluating a model for pharmaceutical care in Australian community pharmacies. Int J Pharm Pract 1999;7(4):220–9.
2.
go back to reference Roberts MS, Stokes JA, King MA, Lynne TA, Purdie DM Glasziou PP, et al. Outcomes of a randomised controlled trial of a clinical pharmacy intervention in 52 nursing homes. Br J Clin Pharmacol 2001;51(3):257–65 (9) 2001 March.PubMedCrossRef Roberts MS, Stokes JA, King MA, Lynne TA, Purdie DM Glasziou PP, et al. Outcomes of a randomised controlled trial of a clinical pharmacy intervention in 52 nursing homes. Br J Clin Pharmacol 2001;51(3):257–65 (9) 2001 March.PubMedCrossRef
3.
go back to reference Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost of illness model. J Am Pharm Assoc 2001;41(2):192–9. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost of illness model. J Am Pharm Assoc 2001;41(2):192–9.
4.
go back to reference Kohn LT, Corrigan JM, Donaldson MS. To err is human: building a safer health system. Washington DC: National Academy Press; 2000, ISBN: 0309068371. Kohn LT, Corrigan JM, Donaldson MS. To err is human: building a safer health system. Washington DC: National Academy Press; 2000, ISBN: 0309068371.
5.
go back to reference Fatel P, Zed PJ. Drug-related visits to the emergency department: how big is the problem? Pharmacotherapy. 2002;22(7):915–23.CrossRef Fatel P, Zed PJ. Drug-related visits to the emergency department: how big is the problem? Pharmacotherapy. 2002;22(7):915–23.CrossRef
6.
go back to reference Australian Council for Safety and Quality in Health Care. Second national report on patient safety: improving medication safety; 2002. Australian Council for Safety and Quality in Health Care. Second national report on patient safety: improving medication safety; 2002.
7.
go back to reference Etemand LR, Hay JW. Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program. Value Health 2003;6(4):425–35 Jul–Aug.CrossRef Etemand LR, Hay JW. Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program. Value Health 2003;6(4):425–35 Jul–Aug.CrossRef
8.
go back to reference Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice. New York: McGraw Hill; 1998, ISBN:0070120463. Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice. New York: McGraw Hill; 1998, ISBN:0070120463.
9.
go back to reference Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice: the clinicians guide. 2nd ed. New York: McGraw-Hill; 2004, ISBN: 0071362592. Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice: the clinicians guide. 2nd ed. New York: McGraw-Hill; 2004, ISBN: 0071362592.
10.
go back to reference Strand LM, Cipolle RJ, Morley PC, Frakes MJ. The impact of pharmaceutical care practice on the practitioner and the patient in the ambulatory practice setting: twenty five years of experience. Curr Pharm Des 2004;10(31):3987–4001.PubMedCrossRef Strand LM, Cipolle RJ, Morley PC, Frakes MJ. The impact of pharmaceutical care practice on the practitioner and the patient in the ambulatory practice setting: twenty five years of experience. Curr Pharm Des 2004;10(31):3987–4001.PubMedCrossRef
12.
go back to reference Chicano P. Identificación y resolución de problemas relacionados con los medicamentos. Experiencia en un centro de salud. (Identification and resolution of drug related problems: experience in a health center). Pharm Care Esp 2002;4:300–13. Chicano P. Identificación y resolución de problemas relacionados con los medicamentos. Experiencia en un centro de salud. (Identification and resolution of drug related problems: experience in a health center). Pharm Care Esp 2002;4:300–13.
14.
go back to reference Gilbert AL, Beilby J, Mott K. Quality use of medicines in the community: an implementation trial about collaborative medication management services, final report to the commonwealth department of health and aged care. 2000. Gilbert AL, Beilby J, Mott K. Quality use of medicines in the community: an implementation trial about collaborative medication management services, final report to the commonwealth department of health and aged care. 2000.
15.
go back to reference Practice Management Information Corporation. International classification of diseases, 9th revision. Clinical modification (ICD-9-CM). 6th ed. Los Angeles: CA; 2004. Practice Management Information Corporation. International classification of diseases, 9th revision. Clinical modification (ICD-9-CM). 6th ed. Los Angeles: CA; 2004.
16.
go back to reference Commonwealth Department of Health and Aged Care. Australian statistics on medicine. Canberra: Ausinfo; 1999. Commonwealth Department of Health and Aged Care. Australian statistics on medicine. Canberra: Ausinfo; 1999.
17.
go back to reference Doucette WR, McDonough RP, Klepser D, McCarthy R. Comprehensive medication therapy management: identifying and resolving drug-related issues in a community pharmacy. Clin Ther 2005;27(7):1104–11. Doucette WR, McDonough RP, Klepser D, McCarthy R. Comprehensive medication therapy management: identifying and resolving drug-related issues in a community pharmacy. Clin Ther 2005;27(7):1104–11.
18.
go back to reference Paulino EI, Bouvy ML, Gastelurrutia MA, Guerreiro M, Buurma H. Drug related problems identified by European community pharmacists in patients discharged from hospital. Pharm World Sci 2004;26(6):353–60.PubMed Paulino EI, Bouvy ML, Gastelurrutia MA, Guerreiro M, Buurma H. Drug related problems identified by European community pharmacists in patients discharged from hospital. Pharm World Sci 2004;26(6):353–60.PubMed
19.
go back to reference Westerlund T, Almarsdottir AB, Melander A. Factors influencing the detection rate of drug-related problems in community pharmacy. Pharm World Sci 1999;21:245–50.PubMedCrossRef Westerlund T, Almarsdottir AB, Melander A. Factors influencing the detection rate of drug-related problems in community pharmacy. Pharm World Sci 1999;21:245–50.PubMedCrossRef
Metadata
Title
Drug therapy problems found in ambulatory patient populations in Minnesota and South Australia
Authors
Deepa Rao
Andrew Gilbert
Linda M. Strand
Robert J. Cipolle
Publication date
01-12-2007
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 6/2007
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-007-9123-1

Other articles of this Issue 6/2007

International Journal of Clinical Pharmacy 6/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine